Cambridge Healthtech Institute’s Inaugural

Emerging Immuno-Oncology Targets

Novel Targets and Pathways for Cancer Immunotherapy and Combinations
August 31 - September 1, 2017 | Sheraton Boston | Boston, MA

While cancer immunotherapy has made a giant leap in the past five years, the majority of therapies at advanced stages of development are clustered in a similar target space. The increased investment in immuno-oncology has created an urgent opportunity to discover and populate new target spaces that either present new classes of immunotherapies or can be used in combination with existing products. Cambridge Healthtech Institute’s Inaugural Emerging Immuno-Oncology Targets conference will cover the emerging target space, including immunomodulatory inhibitor and agonist targets, stromal and immune cell targets, and strategies for rational combination immunotherapy. Case studies of preclinical and translational approaches to the discovery and validation of new immuno-oncology targets and combinations will be presented.

Preliminary Agenda


IMMUNE CHECKPOINT INHIBITORS: BEYOND PD-L1

TIM3 Biology in Myeloid Cells and Implications for TIM3 Blockade in Immuno-Oncology

Xiaomo Jiang, Ph.D., Investigator, Immuno-Oncology, Novartis Institutes for BioMedical Research

New Immune Checkpoints for Human Cancer Immunotherapy

Xingxing Zang, Ph.D., Associate Professor, Microbiology and Immunology & Medicine, Albert Einstein College of Medicine

EMERGING INVESTIGATOR: Targeting IDO1 to Enhance Cancer Immunotherapy: Not So Simple After All

Derek A. Wainwright, Ph.D., Assistant Professor, Departments of Neurological Surgery, Microbiology-Immunology, and Division of Hematology-Oncology, Northwestern University Feinberg School of Medicine


IMMUNOMODULATORY AGONIST TARGETS

Preclinical and Clinical Activity of the CD27 Agonist Antibody Varlilumab

Tibor Keler, Ph.D., Senior Vice President & CSO, Celldex Therapeutics

Clinical Cancer Immunotherapeutic Approaches Utilizing STING-Activating Cyclic Dinucleotides and Live-Attenuated Listeria-Based Platforms to Target Tumor-Specific Neoantigens

Laura Hix Glickman, Ph.D., Senior Scientist, Aduro Biotech


EMERGING TARGETS FOR COMBINATION IMMUNOTHERAPY

Beyond Immune Checkpoint: Co-Targeting Soluble NKG2D Pathway for Cancer Immunotherapy

Jennifer Wu, Ph.D., Professor, Microbiology and Immunology, Medical University of South Carolina

Costimulatory T-Cell Engagement by the 4-1BB/HER2 bispecific PRS-343 for Tumor Localized Activation of the Immune System

Shane Olwill, Ph.D., Vice President, Head of Development & Immuno-Oncology, Pieris Pharmaceuticals GmbH


NEOANTIGEN TARGETED THERAPIES

Development of Monoclonal Antibodies Targeting Functional Neoantigens in Solid Tumors

Philip M. Arlen, M.D., President & CEO, Precision Biologics

Antigen Cascade – Using Self-Antigen Directed Vaccines to Target Neoepitopes

Christopher R. Heery, M.D., CMO, Bavarian Nordic

High-Throughput Functional Screening of Neoantigens for Vaccines and TCR-Based Adoptive T Cell Therapies

Dolores J. Schendel, Ph.D., CEO & CSO, Medigene

Comprehensive Profiling of T Cell Responses to Putative Neoantigens Reveals Smarter Targets for Cancer Immunotherapy

Theresa Zhang, Ph.D., Vice President, Personalized Cancer Vaccines, Genocea Biosciences




For more details on the conference, please contact:
Julia Boguslavsky
Executive Director, Conferences
juliab@healthtech.com

For exhibit & sponsorship opportunities, please contact: 
 
Rod Eymael
Manager, Business Development
781-247-6286
reymael@healthtech.com

YouTubeOutlookYouTubeLinkedInTwitter #IOSummit  

Japan-Flag   Korea-Flag   China-Simplified-Flag   China-Traditional-Flag

Register Today